Literature DB >> 10792238

Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel.

C Y Chu1, C H Yang, C Y Yang, G H Hsiao, H C Chiu.   

Abstract

Docetaxel (Taxotere), a semisynthetic taxoid, acts as an antimicrotubule agent and is considered to have great potential in the treatment of non-small cell lung cancer, advanced breast cancer, ovarian cancer and some other tumours. Well-recognized side-effects include dose-limiting neutropenia, fluid retention, myalgia, neuropathy, hypersensitivity reaction, alopecia, mucositis, nail changes and cutaneous reactions such as acral erythema. We describe a unique docetaxel-induced cutaneous reaction presenting as fixed erythematous plaque(s) unrelated to extravasation or previous skin injury; histopathological studies were performed in three of the four cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792238     DOI: 10.1046/j.1365-2133.2000.03432.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  [Palmoplantar erythrodysesthesia after intravenous therapy with docetaxel].

Authors:  S Meller; J Reifenberger; H Stege; T Ruzicka; B Homey
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

Review 2.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

3.  Rat injury model of docetaxel extravasation.

Authors:  Jing-Jing Zhu; Jian-Fei Fu; Jiao Yang; Bing Hu; Hui Zhang; Jian-Hua Yu
Journal:  Biomed Rep       Date:  2014-05-26

4.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

5.  Optimization of parameters for preparation of docetaxel-loaded PLGA nanoparticles by nanoprecipitation method.

Authors:  Wei Shi; Zhan-Jie Zhang; Yin Yuan; En-Ming Xing; You Qin; Zhen-Jun Peng; Zhi-Ping Zhang; Kun-Yu Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

6.  Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond.

Authors:  Arehalli S Manjappa; Peeyush N Goel; Makam P Vekataraju; Kesarla S Rajesh; Kinjal Makwana; Mukesh Ukawala; Yuvraj Nikam; Rajiv P Gude; Rayasa S Ramachandra Murthy
Journal:  Pharm Res       Date:  2013-06-12       Impact factor: 4.200

7.  Docetaxel-induced hand foot syndrome: "No dose is a safe dose".

Authors:  Ankit Jain; Biswajit Dubashi
Journal:  J Pharmacol Pharmacother       Date:  2012-04

8.  Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited.

Authors:  Elisa Ríos-Viñuela; Eduardo Bernia; Tomás Toledo-Pastrana; Celia Requena; Adrián Diago; Carlos Serra-Guillén; Beatriz Llombart; Victor Traves; Eduardo Nagore; Carlos Guillén; Onofre Sanmartin
Journal:  Acta Derm Venereol       Date:  2021-04-12       Impact factor: 3.875

Review 9.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer.

Authors:  Maria Y Ho; John R Mackey
Journal:  Cancer Manag Res       Date:  2014-05-27       Impact factor: 3.989

10.  Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: in vitro and in vivo evaluation.

Authors:  Hao Wang; Yongdong Xu; Xiao Zhou
Journal:  Int J Mol Sci       Date:  2014-02-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.